The core standard clauses and clinical requirements of this whitepaper are derived from the official document Healthy Longevity Medicine Clinic Standard (Ref: DOH/SD/HLMCS/HCF/V1/2024) formally released by the Department of Health – Abu Dhabi (DoH) in October 2024. Upholding academic rigor, TASCAP fully preserves the statutory name, publication date (October 2024), and effective date (April 2025) of the original standard, and adopts it as an international benchmark reference for compliant clinic development across the Asia-Pacific region.
1. Background and Significance of the Original Standard
In October 2024, the Department of Health – Abu Dhabi (DoH) formally released the Healthy Longevity Medicine Clinic Standard, with full mandatory implementation set from April 2025. This is the world's first regulatory standard specifically governing Healthy Longevity Medicine Clinics issued by a national health authority, marking the transition of longevity medicine from experiential wellness into a government-mandated, formal medical service system.
2. Core Definitions and Scientific Framework
- Healthy Longevity Medicine: an approach that combines preventive and therapeutic medical practice to target the biology of aging across the lifespan, delaying the onset of age-related disease and optimizing Healthspan.
- Healthspan: the period during which an individual maintains good physical and cognitive function in the absence of major disease or disability.
- Biological Age: the actual functional state of the body as determined by molecular, physiological, and digital biomarkers, which more accurately predicts health status and mortality risk than Chronological Age.
3. Client Eligibility and Safety Controls
- Eligible population: individuals aged 18 and above seeking health optimization and aging intervention (clients / patients).
- Exclusion and contraindicated populations: those receiving palliative / hospice care; those with severe cognitive impairment unable to follow safety instructions; pregnant individuals; those in the acute phase of severe cardiovascular disease; those undergoing oncological chemo / radiotherapy; and those who have suffered a major acute illness within the past 3 months.
- Patients with stable chronic disease may be enrolled under shared co-management with the consent of their primary physician.
4. Multidisciplinary Team (MDT) Qualification Requirements
| Team Role | Mandatory Qualification Requirements per Original Standard | Responsibilities and Functions |
|---|---|---|
| Lead Physician | Completion of specialist training with at least 5 years of relevant clinical experience, or completion of systematic training in longevity medicine / lifestyle medicine. | Clinical assessment, risk management, and formulation of personalized intervention prescriptions. |
| Registered Nurse | Holds a DoH practice license, with Advanced Life Support (ALS) certification and cybersecurity training accreditation. | Treatment execution, patient education, and vital sign monitoring. |
| Clinical Nutritionist | Registered qualification, with expertise in precision nutrition and body composition regulation. | Dietary prescriptions based on metabolic and BIA data. |
| Physical Therapist | Background in exercise physiology or rehabilitation. | Muscle mass assessment, VO2 Max cardiorespiratory training, and resistance programs. |
| Clinical Pharmacist | Senior pharmacist qualification. | Assessment of drug – supplement interactions and optimization of drug-repurposing regimens. |
Continuing education requirement: healthcare professionals must earn at least 10 longevity medicine CME credits annually (in addition to baseline license renewal credits).
5. Three-Tier Classification of Diagnostics and Interventions
5.1 Diagnostic Assessment Classification
- Mandatory: medical history questionnaire, physical examination, BIA body composition, comprehensive biochemistry (liver / kidney function, blood glucose, HbA1c, lipids), full hormone panel (TSH, FT4, FT3, cortisol, sex hormones, DHEA-S, IGF-1), inflammatory markers (hs-CRP, ESR), and risk questionnaires (Q-Risk, Framingham, Test2Prevent).
- Optional / Recommended: VO2 Max cardiorespiratory fitness, DEXA bone density, cardiovascular imaging, guideline-based cancer screening, FDA-approved wearable sleep monitoring, and high-risk genetic screening (BRCA1/2, APOE).
- Needs Validation: DNA methylation clock, telomere length, SASP senescent cell count, liquid biopsy, and whole-body MRI.
5.2 Intervention Classification
| Tier | Category | Description |
|---|---|---|
| Green (Applicable) | Precision nutrition, exercise prescription, sleep optimization, mindfulness-based stress reduction, environmental toxin avoidance, and approved-use medications. | Well-evidenced and suitable for routine clinical use. |
| Yellow (Caution / Per Clinic Policy) | Drug repurposing (off-label use such as metformin / rapamycin), oral dietary supplements, NAD+ / vitamin intravenous infusion, and hyperbaric oxygen therapy (HBOT). | Requires human-validated RCT data, with strict adherence to shared decision-making and informed consent. |
| Red (Currently Not Applicable / Not for Routine Clinical Use) | Intravenous stem cell infusion, gene therapy, exosome injection, plasmapheresis, and ozone therapy. | Strictly limited to approved ethical research protocols. |
6. TASCAP Statement
This whitepaper is a professional interpretation and promotion of the official standard DOH/SD/HLMCS/HCF/V1/2024 issued by the Department of Health – Abu Dhabi. All intellectual property rights to the original standard belong to the Department of Health – Abu Dhabi.